查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2048196

僵直性脊椎炎治療市場－全球產業規模、佔有率、趨勢、機會、預測：按藥物、最終用途、地區和競爭對手分類，2021-2031年

Ankylosing Spondylitis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug, By End Use, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球僵直性脊椎炎治療市場預計將從 2025 年的 78.8 億美元大幅成長至 2031 年的 112.7 億美元，複合年成長率為 6.15%。

該市場涵蓋多種旨在減輕發炎和預防脊椎融合的治療方法，例如非類固醇消炎劑 ( NSAIDs)、生物製藥（如 TNF 和 IL 抑制劑）以及Janus激酶抑制劑。推動這一成長的關鍵因素包括全球自體免疫疾病盛行率的上升以及易患慢性發炎性疾病的老年人口的成長。此外，診斷能力的提高和醫療專業人員意識的增強使得疾病的早期發現和早期療育成為可能，從而使更多患者能夠接受先進的藥物治療，這也進一步促進了市場成長。

市場概覽
預測期 2027-2031
市場規模：2025年 78.8億美元
市場規模：2031年 112.7億美元
複合年成長率：2026-2031年 6.15%
成長最快的細分市場 非類固醇消炎劑（NSAIDs）
最大的市場 北美洲

儘管生物製藥市場成長迅速，但其帶來的沉重經濟負擔仍是市場擴張的主要障礙。這限制了患者獲得治療的機會，並給全球醫療報銷體系帶來壓力。此外，難治性疾病的存在使治療方案更加複雜，也加劇了這項挑戰。歐洲風濕病協會聯盟於2025年發布的德國兔登記數據顯示，即使採用標準治療，約有8.5%的中軸型脊椎關節炎患者仍難以控制病情。這凸顯了有效治療對現有治療方法反應不佳的患者這一持續存在的臨床挑戰。

市場促進因素

市場成長的關鍵促進因素是生物製藥和其他標靶治療的日益普及。這些先進的藥物療法，例如Janus激酶抑制劑，對那些對傳統非類固醇消炎劑(NSAIDs) 反應不佳的患者俱有卓越的療效。領先的製藥公司從這些專業產品線獲得了顯著的收入成長，這反映出臨床治療方法的偏好正在轉變，即不僅要緩解症狀，還要積極抑制疾病活動。例如，艾伯維 (AbbVie) 在 2024 年 10 月發布的 2024 年第三季財報中指出，Rinvoq 的全球淨銷售額達到 16.1 億美元，年成長 45.3%。這主要歸功於其在僵直性脊椎炎適應症方面的成功，顯示標靶口服療法在慢性發炎治療中的重要性日益凸顯。

推動市場動態還包括強大的臨床開發平臺以及隨後推出的新型療法。創新正從腫瘤壞死因子抑制劑轉向更精準的雙效細胞激素，這些細胞因子靶向特定的發炎通路，近期核准療法的快速上市便印證了這一點。根據優時比（UCB）於2024年7月發布的“2024年上半年財務業績報告”，新藥bimekizumab的淨銷售額達到2.15億歐元，凸顯了新一代生物製藥對市場的直接影響。此外，現有治療方法也正在擴大市場佔有率。諾華公司報告稱，其白細胞介素抑制劑Cosentyx在2024年第三季的銷售額成長了28%（不計外匯波動的影響），證實了免疫學領域的持續需求。

市場挑戰

僵直性脊椎炎治療市場成長的主要障礙是治療該疾病帶來的沉重經濟負擔。使用昂貴的生物製藥治療給醫療報銷系統造成了巨大壓力，導致保險覆蓋範圍有限，患者難以獲得這些高價值治療方法。此外，整體醫療成本的增加和效率的降低進一步加劇了這種經濟負擔，從而進一步減少了原本可用於先進藥物療法的資源。

醫療保健系統面臨的嚴重經濟影響顯而易見，加拿大僵直性脊椎炎協會估計，到2025年，中軸型脊椎關節炎的年度經濟成本將達到20.1億美元。面對支出激增，支付方和保險公司越來越傾向於將成本控制置於引入昂貴新治療方法之上。這些經濟限制直接縮小了高價藥物的適用範圍，從而減緩了市場收入成長。因此，儘管臨床上已有有效的治療方法，但該領域仍無法充分發揮其商業性潛力。

市場趨勢

重塑市場格局的關鍵趨勢之一是經濟實惠的生物相似藥的日益普及。這些藥物為昂貴的原廠生物製藥提供了更具經濟吸引力的替代方案。隨著主要腫瘤壞死因子抑制劑的專利保護期到期，醫療系統和支付方越來越支持這些價格更親民的選擇，以應對治療慢性自體免疫疾病日益成長的預算壓力。這項策略轉變正在推動生物相似藥的快速商業性化應用，並改善了患者獲得先前因成本限制而難以企及的生物製藥療法的機會。例如，根據山德士公司於2025年3月發布的《2024年山德士財務報告》，生物相似藥的淨銷售額達到29億美元，按外匯調整後年增30%。這表明，在主要市場，對Hyrimoz等經濟實惠的治療方法有著強勁的需求。

此外，人工智慧驅動的診斷和研發工具的整合正在顯著提升僵直性脊椎炎新療法的發現速度和準確性。製藥公司正擴大利用人工智慧來揭示複雜的發炎通路，並最佳化有前景的候選藥物篩選，從而顯著縮短通常漫長的藥物研發週期。這種營運模式的轉變體現在與人工智慧原生生物技術公司進行的大量合作投資上，旨在尋找自體免疫疾病的新治療標靶。例如，根據BioWorld在2026年1月報道，賽諾菲與一家人工智慧驅動的生物技術公司合作，將利用該平台發現自體免疫疾病和發炎性疾病的新治療方法，潛在合約金額高達25.6億美元。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：僵直性脊椎炎治療藥物的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 透過藥物（Cosentyx、Humira、Simpni、 Remicade、 Enbrel、 Cimzia）
    • 依用途（醫院、診所、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美僵直性脊椎炎治療藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲僵直性脊椎炎治療藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區僵直性脊椎炎治療藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲僵直性脊椎炎治療藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲僵直性脊椎炎治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球僵直性脊椎炎治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • AbbVie Inc.
  • Amgen Inc.
  • F. Hoffmann-La Roche Ltd.
  • Pfizer Inc.
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • UCB SA
  • Sanofi SA
  • Eli Lilly and Company
  • Bristol-Myers Squibb Compan

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 16738

The global market for Ankylosing Spondylitis therapeutics is projected to expand significantly, rising from USD 7.88 Billion in 2025 to USD 11.27 Billion by 2031, at a Compound Annual Growth Rate of 6.15%. This market includes various pharmaceutical treatments such as nonsteroidal anti-inflammatory drugs, biologics like TNF and IL inhibitors, and Janus kinase inhibitors, all aimed at reducing inflammation and preventing spinal fusion. Key factors fueling this growth include an increasing worldwide prevalence of autoimmune disorders and a growing elderly population more prone to chronic inflammatory conditions. Enhanced diagnostic capabilities and greater awareness among healthcare professionals further contribute by enabling earlier detection and intervention, consequently expanding the number of patients eligible for advanced drug therapies.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 7.88 Billion
Market Size 2031USD 11.27 Billion
CAGR 2026-20316.15%
Fastest Growing SegmentNon-steroidal anti-inflammatory drugs (NSAID)
Largest MarketNorth America

Despite this growth, a major obstacle to market expansion is the considerable financial strain linked to biologic therapies, which restricts patient access and pressures global healthcare reimbursement systems. The challenge is compounded by the existence of refractory disease, which complicates treatment approaches. As evidenced by data from the German Rabbit register presented in 2025 by the European Alliance of Associations for Rheumatology, roughly 8.5% of patients with axial spondyloarthritis were deemed challenging to manage even with standard care. This highlights the ongoing clinical difficulty in effectively treating patients who do not respond sufficiently to current therapeutic options.

Market Driver

A significant driver of market growth is the growing use of biologics and other targeted therapies. These advanced pharmacotherapies, such as Janus kinase inhibitors, provide superior effectiveness for patients who do not respond well to traditional nonsteroidal anti-inflammatory drugs. Major pharmaceutical companies are experiencing substantial revenue increases from these specialized product lines, reflecting a shift in clinical preference towards treatments that actively modify disease activity rather than just alleviating symptoms. For example, AbbVie reported in its 'Third-Quarter 2024 Financial Results' in October 2024 that Rinvoq's global net revenues reached 1.61 billion dollars, a 45.3 percent increase year-over-year, largely due to its success in indications like ankylosing spondylitis, demonstrating the rising importance of targeted oral therapies for chronic inflammation.

Further boosting market dynamics is a strong clinical development pipeline and the subsequent introduction of new therapeutic agents. Innovation is progressing beyond tumor necrosis factor inhibitors, moving towards more precise dual-action cytokines that target specific inflammatory pathways, as shown by the rapid commercial adoption of recently approved treatments. UCB's '2024 Half-Year Financial Report' in July 2024 indicated that net sales for the new bimekizumab reached 215 million Euros, underscoring the immediate market influence of next-generation biologics. Moreover, established therapies are also broadening their market presence; Novartis reported in 2024 that third-quarter sales for the interleukin inhibitor Cosentyx rose by 28 percent in constant currencies, confirming ongoing demand within the immunology sector.

Market Challenge

A primary obstacle to the growth of the ankylosing spondylitis therapeutics market is the significant economic strain related to managing the condition. Expensive biologic treatments exert considerable pressure on healthcare reimbursement systems, resulting in restrictive coverage policies and consequently limiting patient access to these high-value therapies. This financial burden is compounded by the wider costs of overall care and lost productivity, which further diminish resources that could otherwise be allocated to advanced pharmacotherapy.

The severe financial implications for health systems are evident, with the Canadian Spondyloarthritis Association estimating in 2025 an annual economic cost of $2.01 billion attributed to axial spondyloarthritis. Facing these escalating expenditures, payers and insurance providers often prioritize cost-containment strategies over the adoption of new, costly treatments. These economic limitations directly shrink the accessible patient base for premium drugs and slow down market revenue growth, ultimately hindering the sector from reaching its full commercial potential despite the clinical availability of effective treatments.

Market Trends

A key trend reshaping the market is the increasing availability of cost-effective biosimilars, which offer financially attractive alternatives to high-priced reference biologics. As patent exclusivity for major tumor necrosis factor inhibitors expires, healthcare systems and payers are actively favoring these more affordable options to manage the rising budgetary impact of chronic autoimmune care. This strategic shift is fueling rapid commercial adoption and enhancing patient access to biologic therapies that were previously unaffordable due to cost constraints. For instance, Sandoz's 'Sandoz Financial Report 2024' in March 2025 revealed that biosimilar net sales reached $2.9 billion, a 30 percent increase in constant currencies from the prior year, demonstrating robust demand for cost-efficient treatments such as Hyrimoz in critical markets.

Additionally, the integration of AI-driven diagnostic and development tools is transforming the speed and accuracy with which new ankylosing spondylitis therapeutics are discovered. Pharmaceutical companies are increasingly leveraging artificial intelligence to unravel intricate inflammatory pathways and refine the selection of lead drug candidates, thereby significantly reducing the typically long drug discovery period. This operational change is marked by considerable investments in partnerships with AI-native biotechnology firms, aimed at identifying novel therapeutic targets for autoimmune conditions. An example of this is Sanofi's partnership, reported by BioWorld in January 2026, a deal potentially worth $2.56 billion, to utilize an AI-driven platform for discovering new treatments for autoimmune and inflammatory diseases.

Key Market Players

  • AbbVie Inc.
  • Amgen Inc.
  • F. Hoffmann-La Roche Ltd.
  • Pfizer Inc.
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • UCB S.A.
  • Sanofi S.A.
  • Eli Lilly and Company
  • Bristol-Myers Squibb Compan

Report Scope

In this report, the Global Ankylosing Spondylitis Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Ankylosing Spondylitis Therapeutics Market, By Drug

  • Cosentyx
  • Humira
  • Simponi
  • Remicade
  • Enbrel
  • Cimzia

Ankylosing Spondylitis Therapeutics Market, By End Use

  • Hospitals
  • Clinics
  • Others

Ankylosing Spondylitis Therapeutics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Ankylosing Spondylitis Therapeutics Market.

Available Customizations:

Global Ankylosing Spondylitis Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Ankylosing Spondylitis Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug (Cosentyx, Humira, Simponi, Remicade, Enbrel, Cimzia)
    • 5.2.2. By End Use (Hospitals, Clinics, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Ankylosing Spondylitis Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug
    • 6.2.2. By End Use
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Ankylosing Spondylitis Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug
        • 6.3.1.2.2. By End Use
    • 6.3.2. Canada Ankylosing Spondylitis Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug
        • 6.3.2.2.2. By End Use
    • 6.3.3. Mexico Ankylosing Spondylitis Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug
        • 6.3.3.2.2. By End Use

7. Europe Ankylosing Spondylitis Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug
    • 7.2.2. By End Use
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Ankylosing Spondylitis Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug
        • 7.3.1.2.2. By End Use
    • 7.3.2. France Ankylosing Spondylitis Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug
        • 7.3.2.2.2. By End Use
    • 7.3.3. United Kingdom Ankylosing Spondylitis Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug
        • 7.3.3.2.2. By End Use
    • 7.3.4. Italy Ankylosing Spondylitis Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug
        • 7.3.4.2.2. By End Use
    • 7.3.5. Spain Ankylosing Spondylitis Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug
        • 7.3.5.2.2. By End Use

8. Asia Pacific Ankylosing Spondylitis Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug
    • 8.2.2. By End Use
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Ankylosing Spondylitis Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug
        • 8.3.1.2.2. By End Use
    • 8.3.2. India Ankylosing Spondylitis Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug
        • 8.3.2.2.2. By End Use
    • 8.3.3. Japan Ankylosing Spondylitis Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug
        • 8.3.3.2.2. By End Use
    • 8.3.4. South Korea Ankylosing Spondylitis Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug
        • 8.3.4.2.2. By End Use
    • 8.3.5. Australia Ankylosing Spondylitis Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug
        • 8.3.5.2.2. By End Use

9. Middle East & Africa Ankylosing Spondylitis Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug
    • 9.2.2. By End Use
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Ankylosing Spondylitis Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug
        • 9.3.1.2.2. By End Use
    • 9.3.2. UAE Ankylosing Spondylitis Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug
        • 9.3.2.2.2. By End Use
    • 9.3.3. South Africa Ankylosing Spondylitis Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug
        • 9.3.3.2.2. By End Use

10. South America Ankylosing Spondylitis Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug
    • 10.2.2. By End Use
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Ankylosing Spondylitis Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug
        • 10.3.1.2.2. By End Use
    • 10.3.2. Colombia Ankylosing Spondylitis Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug
        • 10.3.2.2.2. By End Use
    • 10.3.3. Argentina Ankylosing Spondylitis Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug
        • 10.3.3.2.2. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Ankylosing Spondylitis Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. AbbVie Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Amgen Inc.
  • 15.3. F. Hoffmann-La Roche Ltd.
  • 15.4. Pfizer Inc.
  • 15.5. Johnson & Johnson Services, Inc.
  • 15.6. Novartis AG
  • 15.7. UCB S.A.
  • 15.8. Sanofi S.A.
  • 15.9. Eli Lilly and Company
  • 15.10. Bristol-Myers Squibb Compan

16. Strategic Recommendations

17. About Us & Disclaimer